Although blockade of the Kv11.1 channel negatively affects cancer growth [10], the use of Kv11.1 blocker molecules is discouraged for cancer therapy due to the high risk of severe side effects linked to Kv11.1 function loss, including ventricular fibrillation [11]. This evidence concerns the gene KCNH2 and ventricular fibrillation.